Clinical Trials Directory

Trials / Completed

CompletedNCT01576120

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients

Evaluation of a PillCam Colon Bowel Preparation Regimen in Crohn's Disease Patients- Pivotal Study

Status
Completed
Phase
Phase 1 / Phase 2
Study type
Interventional
Enrollment
40 (actual)
Sponsor
Medtronic - MITG · Industry
Sex
All
Age
18 Years – 75 Years
Healthy volunteers
Not accepted

Summary

The proposed study is designed to evaluate Pillcam regimen in Crohn's disease patients, using the PillCam Colon system.

Detailed description

1. Primary Scientific Objective Evaluate the effectiveness of the PillCam COLON 2 Prep Regimen in CD patients. Secondary Objective To evaluate safety of the PillCam™ COLON 2 procedure in CD patients 2. Study Hypothesis Crohn's Disease may be pan-enteric in nature and can affect the small bowel, the colon or both. PillCam COLON 2 may be used for visualization of both SB and colon mucosa in Crohn's Disease patients. However, bowel prep is required in order to evacuate all fecal matter prior to the exam and in order to propel the capsule and complete its traverse through the entire GI track within examination time. 3. The study is designed to evaluate the effectiveness of the prep regimen in terms of transit, excretion and cleansing in CD patients All end points will be evaluated within 4 months from end of enrollment.

Conditions

Interventions

TypeNameDescription
OTHERbowel prep regimen first boost 6 oz. and second boost 3 oz.Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. In this arm the subjects administered a 6 oz. dose of Suprep as first boost and if needed addtional 3 oz. of Suprep (second boost)
OTHERbowel prep regimen first boost 3 oz. and second boost 6 oz.Subjects will be instructed to perform the bowel preparation procedure and follow a detailed dietary regimen prior to and during the CE procedure. In this arm the subjects administered a 3 oz. dose of Suprep as first boost and if needed addtional 6 oz. of Suprep (second boost)

Timeline

Start date
2012-03-01
Primary completion
2014-07-01
Completion
2014-07-01
First posted
2012-04-12
Last updated
2019-08-08
Results posted
2014-10-09

Locations

2 sites across 1 country: United States

Source: ClinicalTrials.gov record NCT01576120. Inclusion in this directory is not an endorsement.